Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival
Pooled Analysis of 12 Seperate Yervoy Studies Shows Survival-Curve Plateau at 3 Years
Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer
ASCO and CAP Issue Guideline To Improve HER2 Testing
Phase III Ramucirumab Trial Fails Primary Endpoint of PFS
Kadcyla Extends Median PFS In Open-Label Phase III Trial
Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease
Colon Polyps in Elderly Patients Are More Likely to Be Found Only with Colonoscopy
Phase III Vaccine Trial Fails To Improve Overall Survival
Central Line Safety Intervention Lowers Patient Infection Rate
Phase II Study Shows Positive Results in Reducing Dry Mouth
NCI CTEP Approved Trials For the Month of October
Trending Stories
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- ACOG says it will no longer accept federal funding
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - When public service ends abruptly, do books provide solace? An escape? Perspective?
Former NIH and FDA employees tell us what they are reading in 2025 - Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death - The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”
